PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease Post published:February 1, 2023 Post category:Press Release
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome Post published:January 18, 2023 Post category:Press Release
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation Post published:January 8, 2023 Post category:Press Release
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome Post published:November 2, 2022 Post category:Press Release
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease Post published:October 5, 2022 Post category:Press Release
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022 Post published:September 29, 2022 Post category:Press Release
PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson’s Disease and Movement Disorders® Post published:September 16, 2022 Post category:Press Release
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch Post published:September 7, 2022 Post category:Press Release
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders Post published:July 13, 2022 Post category:Press Release
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch Post published:July 5, 2022 Post category:Press Release